Allergan Says Botox Label Expanded to Treat Pediatric Patients with Spasticity
July 09 2020 - 7:29PM
Dow Jones News
By Stephen Nakrosis
Allergan on Thursday said the U.S. Food and Drug Administration
approved an expansion to the label for Botox, to include "the
treatment of spasticity in pediatric patients two years of age and
older."
The company said the label expansion includes those patients
"with lower limb spasticity caused by cerebral palsy."
Botox hasn't been shown "to improve upper extremity functional
abilities, or range of motion at a joint affected by a fixed
contracture," the company said.
Allergan also said, "This label expansion is based on Allergan
and another manufacturer selectively waiving orphan exclusivity
marketing rights each company held for the use of their respective
neurotoxins in the treatment of pediatric patients with spasticity
caused by cerebral palsy."
Allergan is an AbbVie Inc. company.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 09, 2020 19:14 ET (23:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
